Amarin (AMRN) vs GSK (GSK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GSK (GSK) has outperformed Amarin (AMRN) over the past year, gaining 7.4% versus a loss of 37.8%. Over five years, GSK leads with a +19.3% price change compared with -88.4% for AMRN. GSK is the larger company by market cap ($93.24 billion vs $253.3 million), about 368.2 times the size.
On valuation, GSK trades at a lower forward P/E (9.4x vs 12.2x for Amarin). GSK pays a dividend yielding 1.46%, while Amarin does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | GSK |
|---|---|---|
| Share price | $11.99 | $46.54 |
| Market cap | $253.26M | $93.24B |
| 1-day change | -0.25% | -1.02% |
| YTD return | -14.11% | -5.10% |
| 1-year return | -37.81% | +7.36% |
| 5-year return | -88.38% | +19.30% |
| P/E ratio (TTM) | — | 14.68 |
| Forward P/E | 12.23 | 9.42 |
| EPS (TTM) | $-1.20 | $3.17 |
| Dividend yield | 0.00% | 1.46% |
| Annual dividend | $0.00 | $0.68 |
| 52-week high | $20.90 | $61.70 |
| 52-week low | $11.83 | $42.85 |
| Distance from 52-week high | -42.63% | -24.57% |
| Analyst consensus | none | hold |
| Avg. price target upside | +4.25% | +27.48% |
| Average volume | 66.23K | 3.85M |
| Shares outstanding | 21.12M | 2.00B |
| Employees | 80 | 66,841 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GSK is about 368.2 times larger than Amarin by market value ($93.24B vs $253.26M).
- GSK has outperformed AMRN by 45.2 percentage points over the past year.
- GSK offers a meaningfully higher dividend yield (1.46% vs 0.00%).
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About GSK
GSK stock →GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 66,841 employees
AMRN vs GSK FAQ
Which is bigger, Amarin or GSK?
GSK (GSK) is larger, with a market capitalization of $93.24B compared with $253.26M for Amarin (AMRN).
Which stock has performed better over the past year, AMRN or GSK?
GSK returned +7.36% over the past 12 months, compared with -37.81% for AMRN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Amarin or GSK?
GSK pays a dividend yielding 1.46%, while Amarin does not currently pay a regular dividend.
Are Amarin and GSK in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.